Latest Pro Medicus (ASX:PME) News

Pro Medicus delivered a robust FY26 with 28% underlying revenue growth, a surge in new contract wins worth $407 million, and a 25% increase in fully franked dividends, underpinned by strong AI product development and rapid implementations.

Small explorers led the ASX week, with Lachlan Star, EcoGraf and Basin Energy recording the biggest gains on new drilling, offtake and exploration news.
Takeovers, capital raisings and strong company results also drew attention, although several large stocks fell despite reporting better earnings.

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.

Pro Medicus’ US subsidiary Visage Imaging has landed a 7-year, A$23 million contract to deploy its cloud-based Visage 7 platform across St. Luke’s Health System, marking a further expansion in North America.

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.

Pro Medicus has inked a binding Heads of Agreement with Echo IQ to finance and resell AI algorithms targeting cardiovascular conditions, aiming to integrate these into its Visage 7 Cardiology platform.

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.

Pro Medicus' U.S. subsidiary Visage Imaging has extended its contract with The Ohio State University Wexner Medical Center for five years, adding new Visage 7 modules and increasing transaction fees, underpinning strong client retention and platform demand.

Pro Medicus secures a $16 million, 7-year cloud imaging contract with TidalHealth, complementing recent major wins and contract renewals that underscore its growing dominance in North American healthcare IT.

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

Pro Medicus’ US arm Visage Imaging has landed a significant 7-year, A$90 million contract to deploy its cloud-based Visage 7 platform across Beth Israel Lahey Health, marking another major foothold in North America's healthcare imaging market.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.